CERT vs REGN · rev $385.1M vs P/E 14, rev $14.34B
Certara Inc (CERT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Certara Inc (CERT) is a health information services company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CERT revenue for 2024-12-31 was $385.1M. Net income was -$12.1M. Revenue was up 8.7% from 2023-12-31 to 2024-12-31. CERT currently screens at market cap $1.86B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CERT currently screens at market cap $1.86B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CERT and REGN stock pages for the full models.
Not investment advice.